The PennZone

  • Home
  • Business
  • Health
  • Construction
  • Real Estate
  • Technology
  • Education
  • Travel
  • Non-profit

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • New Report Reveals Surprising Trends in Ohio Airport Accidents
  • JEGS Launches Modern, Secure Payments Powered by PhaseZero.ai
  • Where Were the Women? Reframing the Greek Revolution Through Contemporary Art
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
  • New Book Reveals The Science Of Predictions
  • Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
  • Colony Ridge Communities Celebrates Successful Soccer Season Kickoff with Families and Youth
  • Best Companies Group Free Launches Best Places to Work in Michigan Program

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Meet Joseph Neibich aka Joseph Nybyk of Beachwood Canyon
  • LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
  • KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
  • Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
  • Why We're Holding the Line on Pricing
  • Moravian Academy Announces New Full-Tuition Impact Scholarship for Upper School Students
  • AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
  • National Focus Turns to Global Conflict, Families of Veterans Lost to Suicide Call for Recognition
  • New Global Standard for Transparency Across Critical Resources and Energy Markets: SMX (Security Matters) PLC (N A S D A Q: SMX)
  • Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
  • Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
  • ATTAIN Profiles the Invisible Billionaire Who Started With $75 and Died the Richest Man in A
  • Kiko Nation Launches Mobile App to Modernize Livestock Management and Digital Animal Registry
  • NEW MANAGEMENT BOOK: Creating a Joy-Centric Culture
  • QuickTrack by Datalex Transforms Retail Promoter Management with Claude AI and Real-Time Insights
  • Kaltra Introduces Seasonal Discounts on Replacement Coils for Carrier, York, and Trane Chillers
  • Evolve Construction Mobilizes Commercial Storm Response Across Illinois With AI-Powered Damage Documentation and Public Adjusters Partnership
  • New Book Synthesizes Six Peer-Reviewed Research Programs Into Unified Framework for Consciousness
  • The World's First Fully Regenerative Economy: Securing Energy, Food, and a Clean Planet

Popular on PennZone

  • Postmortem Pathology Expands Independent Autopsy Services Across Colorado
  • Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
  • Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • $38 Million in U.S. Government Contract Awards Secured Through Strategic Partner. Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
  • Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates
  • Inkdnylon Earns BBB Accreditation for Verified Business Integrity
  • IDpack v4 Launches: A Major Evolution in Cloud-Based ID Card Issuance

Similar on PennZone

  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
  • Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
  • The World's First Fully Regenerative Economy: Securing Energy, Food, and a Clean Planet
  • Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
  • Innovative Environmental Technologies Unveils New Website Featuring Free AI Tools for the Environmental Industry
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
  • Strong Clinical Results for Breakthrough Liver Diagnostic Platform; ENDRA Life Sciences (N A S D A Q: NDRA) $NDRA
  • $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
  • Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us